Luye Pharma Group Limited — Capital/Financing Update 2021

Feb 2, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [194 x 87] intentionally omitted <==

LUYE PHARMA GROUP LTD.

綠 葉 製 藥 集 團 有 限 公 司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

DISCLOSEABLE TRANSACTION

COMPLETION OF THIRD PARTIES’ INVESTMENTS IN SHANDONG BOAN

Reference is made to the announcements of Luye Pharma Group Ltd. dated 28 December 2020, 4 January 2021, 18 January 2021 and 26 January 2021 (collectively, the ‘‘Previous Announcements’’) respectively in relation to, among other things, the investment and subscription of equity interests in Shandong Boan (a subsidiary of the Company) by the Investors. Unless otherwise defined herein, capitalised terms used in this announcement have the same meanings ascribed to them in the Previous Announcements.

The Board would like to announce that all respective conditions of the Group A Subscription, the Group B Subscription and the Group C Investments have been fulfilled, and completion has taken place.

By Order of the Board LUYE PHARMA GROUP LTD. Liu Dian Bo Chairman

Hong Kong, 2 February 2021

As at the date of this announcement, the executive Directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive Director of the Company is Mr. SONG Rui Lin; and the independent non-executive Directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.